Press Release: DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026

Dow Jones04-30 20:32
MINNEAPOLIS--(BUSINESS WIRE)--April 30, 2026--

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke $(AIS)$, today announced that its first quarter 2026 financial results will be released after the markets close on Wednesday, May 6(th) . DiaMedica will host a live conference call on Thursday, May 7(th) at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results.

Conference Call details: 

 
Date:            Thursday, May 7, 2026 
Time:            8:00 AM EDT / 7:00 AM CDT 
Web access:      https://app.webinar.net/nG3yPzRP7wk 
Dial In:         (646) 357-8766 
Conference ID:   6195397

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company's website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 14, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 6195397#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260430443041/en/ 

 
    CONTACT:    Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306

mmoyer@lifesciadvisors.com

Media Contact:

Madelin Hawtin

LifeSci Communications

mhawtin@lifescicomms.com

(END) Dow Jones Newswires

April 30, 2026 08:32 ET (12:32 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment